Carbazole scaffolds in cancer therapy: a review from 2012 to 2018
Samar Issa, Anthony Prandina, Nicolas Bedel, Pal Rongved, Saïd Yous, Marc Le Borgne, Zouhair Bouaziz

To cite this version:
Samar Issa, Anthony Prandina, Nicolas Bedel, Pal Rongved, Saïd Yous, et al.. Carbazole scaffolds in cancer therapy: a review from 2012 to 2018. Journal of Enzyme Inhibition and Medicinal Chemistry, Informa Healthcare, 2019, 34 (1), pp.1321-1346. 10.1080/14756366.2019.1640692. hal-02190476

HAL Id: hal-02190476
https://hal.archives-ouvertes.fr/hal-02190476
Submitted on 22 Jul 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Carbazole scaffolds in cancer therapy: a review from 2012 to 2018

Samar Issa, Anthony Prandina, Nicolas Bedel, Pål Rongved, Saïd Yous, Marc Le Borgne & Zouhair Bouaziz

To cite this article: Samar Issa, Anthony Prandina, Nicolas Bedel, Pål Rongved, Saïd Yous, Marc Le Borgne & Zouhair Bouaziz (2019) Carbazole scaffolds in cancer therapy: a review from 2012 to 2018 , Journal of Enzyme Inhibition and Medicinal Chemistry, 34:1, 1321-1346, DOI: 10.1080/14756366.2019.1640692

To link to this article: https://doi.org/10.1080/14756366.2019.1640692

© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

Published online: 22 Jul 2019.

Submit your article to this journal

View Crossmark data
Carbazole scaffolds in cancer therapy: a review from 2012 to 2018

Samar Issa a,b,∗, Anthony Prandina c,d, Nicolas Bedel b, Pål Rongved e, Saïd Yous zouhair.bouaziz@univ-lyon1.fr, Marc Le Borgne b and Zouhair Bouaziz b

Ecole de Biologie Industrielle, EBlinnov, Cergy-Pontoise, France; bFaculté de Pharmacie - ISPB, EA 4446 Bioactive Molecules and Medicinal Chemistry, SFR Santé Lyon-Est CNRS UMS3453 - INSERM US7, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France; cDepartment of Pharmaceutical Chemistry, School of Pharmacy, University of Oslo, Oslo, Norway; dUniversité Lille, Inserm, CHU Lille, UMR-S 1172 JPArc Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, Lille, France

ABSTRACT
For over half a century, the carbazole skeleton has been the key structural motif of many biologically active compounds including natural and synthetic products. Carbazoles have taken an important part in all the existing anti-cancer drugs because of their discovery from a large variety of organisms, including bacteria, fungi, plants, and animals. In this article, we specifically explored the literature from 2012 to 2018 on the anti-tumour activities reported to carbazole derivatives and we have critically collected the most significant data. The most described carbazole anti-tumour agents were classified according to their structure, starting from the tricyclic-carbazole motif to fused tetra-, penta-, hexa- and heptacyclic carbazoles. To date, three derivatives are available on the market and approved in cancer therapy.

1. Introduction
Cancer is characterized by an uncontrolled growth of cells, which can spread to distant sites of the body with severe health consequences and is the second leading cause of death worldwide. Around 14.1 million new cancer cases and 8.2 million cancer-related deaths occurred in 2012, and 29.4 million new cases are estimated for 2035 with 18.8 million cancer-related deaths (GLOBOCAN 2012) 2. The most commonly diagnosed cancers worldwide are those of the lung (1.8 million, 12.6% of the total), breast (1.7 million, 11.9%), colorectal (1.4 million, 9.8%) and prostate (1.1 million, 7.7%) cancers. Keeping in mind that both cancer cases are increasing and resistance to anti-cancer drug regimens are emerging, research and development of new powerful cancer treatments became extremely crucial for the next decades. Among the existing anti-cancer drugs, the carbazole scaffolds have been, for over half a century, the key structural motif of many biologically active compounds including natural and synthetic products. Carbazole alkaloids originate in most cases from higher plants of the genera Murraya, Glycosmis, Clausena and Micromelum, all from the family of Rutaceae. Other sources are bacteria (e.g. Streptomyces), algae (e.g. Hyella caespitosa) and fungi (e.g. Aspergillus species). The parent compound 9H-carbazole was isolated from coal tar in 1872 by Graebe and Glazer. The first naturally occurring carbazole, the alkaloid murrayanine, was isolated from Murraya koenigii Spreng in 1962. Later, many carbazole derivatives have been synthesized and are well known for their pharmacological activities such as anti-oxidant, anti-inflammatory, anti-bacterial, anti-tumour, anti-convulsant, anti-psychotic and anti-diabetic. Many carbazole derivatives and related compounds have been studied. More interestingly, three derivatives have obtained marketing authorization with anti-cancer drug status in different countries. Ellipticine, which was discovered in 1959 (Figure 1) and extracted from the leaves of Ochrosia elliptica (Apocynaceae) before being entirely synthesized, could be considered as the first initial lead compound of carbazole analogues. Thereafter, an ellipticine analogue named N-methyl-9-hydroxylellipticine acetate (Celiptium®) has been developed. Since 1982, Celiptium® is still currently used in the treatment of metastatic breast cancer. As reported by the National Cancer Institute (NCI) drug dictionary, N-methyl-9-hydroxylellipticine acetate acted as a topoisomerase II inhibitor and an intercalating agent, stabilizing the cleavable complex of topoisomerase II and inducing DNA breakages, thereby inhibiting DNA replication and RNA and protein synthesis. New 9-thioalkylcarbazole derivatives were synthesized and evaluated in comparison to ellipticine. Among the bioactive carbazole-type derivatives, 7-(6-bromo-1,4-dimethyl-9H-carbazol-9-yl)-heptane-1-thiol (Figure 1) needs to be also mentioned.

The second derivative to obtain marketing authorization was alectinib bearing a 5H-benzob[cb]carbazol-11(6H)-one scaffold (AF802, CH 5424802, RG7853, RO5424802, Alecensa®) (Figure 2). Alectinib, an orally available drug, was first approved in 2015 by the US Food and Drug Administration (FDA) for Genentech and then by the European Medicines Agency (EMA) for Roche Pharmaceuticals, with an indication as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC).

CONTACT Samar Issa s.issa@hubebi.com, Ecole de Biologie Industrielle, EBlinnov, 49 Avenue des Genottes Cergy-Pontoise CS90099 95895, France; Zouhair Bouaziz zouhair.bouaziz@univ-lyon1.fr, Faculté de Pharmacie - ISPB, EA 4446 Bioactive Molecules and Medicinal Chemistry, Université Claude Bernard Lyon 1, 8 avenue Rockefeller, Lyon cedex 8 F-69373, France

These authors contributed equally to this article.

© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The third derivative recently approved in 2017 by the FDA and the EMA is midostaurin (CGP41251, PKC412, Rydapt) (Novartis) (Figure 3), described mainly as the first fms-like tyrosine kinase 3 (FLT3) inhibitor for newly diagnosed acute myeloid leukemia (AML) and for advanced systemic mastocytosis (SM). Compared to the previously recent published reviews, we focused this article on the carbazole derivatives exerting anti-tumour activity reported from 2012 to 2018, and we critically collected the most significant data. The term "carbazole" includes both the tricyclic molecular skeleton and diverse fused carbazoles including tetracyclic (with 5-, 6- and 7-membered rings), pentacyclic, hexacyclic and finally heptacyclic fused carbazoles (Figure 4).

Several databases, bibliographic information (articles) from namely ScienceDirect, Scifinder, Pubmed and Web of Science as well as technological (patents) information from INPI Patents Database, European Patent Office (EPO), as well as the World Intellectual Property Organization (WIPO), were used as literature sources.

The increased interest in the use of carbazole derivatives for the cancer therapy can also be expressed in the research of patents. In Table 1, the publication of 10 patents – including one European patent, three US patents and seven international patents for carbazole derivatives currently described for their anti-cancer activity.

2. Tricyclic carbazoles

2.1. Ferrocenyl platinum(II) complex
Ferrocenyl platinum(II) complex [Pt(Fc-tpy)(NPC)]Cl (HNPC = N-propargylcarbazole) was synthesized and evaluated for its anti-proliferative properties in visible light against HaCaT (human keratinocyte) cell lines. Compound 1 (Figure 5) exhibited interesting photocytotoxicity in HaCaT cell lines with an IC50 value of 12.0 \( \mu \text{M} \) in visible light (400–700 nm) with low dark toxicity (IC50 > 60 \( \mu \text{M} \)).

2.2. N-Acylcarbazoles
N-Acylated carbazoles were synthesized and evaluated for their anti-proliferative activities against CAL 27 (squamous cell carcinoma) cell lines. The IC50 values of the most active compounds 2a and 2b (Figure 6) were 0.028 and 0.45 \( \mu \text{M} \), respectively.

2.3. 6-Methyl-2,3,4,9-tetrahydro-1H-carbazoles
Tetrahydrocarbazoles were synthesized and tested for anti-cancer activity against six different cell lines, namely human kidney adenocarcinoma (ACHN), pancreas carcinoma (Panc1), lung carcinoma (GIll and Calu1), non-small-cell lung carcinoma (H460), human colon carcinoma (HCT116) and normal breast epithelium (MCF10A) cell lines. Carbazole derivatives demonstrated moderate to good activities and among them, compound 3 (Figure 7) was found to be the most active against Calu1 cell line with an IC50 of 2.5 nM.

2.4. N-[3-[3-\{9-Methyl-9H-carbazol-3-yl\}-acyloyl]-phenyl]-benzamide
These derivatives were synthesized and evaluated for their in vitro xanthine oxidase (XO), tyrosinase and melanin production inhibitory activity. Most of the target compounds (4a, 4c, 4d, 4e, 4g, 4i and 4j) inhibited XO with IC50 values comprised between 4.3 and 5.6 \( \mu \text{M} \). Furthermore, these derivatives showed a better activity than the standard drug allopurinol (IC50 value of 8.5 \( \mu \text{M} \)). Interestingly, compound 4a bearing a cyclopropyl ring was found to be the most potent inhibitor of XO with an IC50 of 4.3 \( \mu \text{M} \). Compounds 4b, 4d, 4f, 4h and 4j were found to be potent inhibitors of tyrosinase (IC50 values ranging from 14.01 to 17.52 \( \mu \text{M} \)). These results suggest the possible use of these compounds for the design and development of novel XO and tyrosinase inhibitors.
2.5. 3,6-Bis(1-methyl-4-vinylpyridinium) carbazole diiodide (BMVC)

BMVC or compound 5 (Figure 9) is known for its ability (i) to suppress the telomerase activity, (ii) to induce senescence of cancer cells and (iii) to destroy the intra-tumour vasculature. BMVC was studied for tumour targeting as well as for its photo-induced anti-tumour effect. The properties of this fluorescent molecule provided a design of photosensitizer (PS) for photodynamic therapy (PDT) treatment. PDT results showed that BMVC inhibited the growth of tumour cells both in vitro and in vivo. BMVC is the most studied to this date as a "G-quadruplex" ligand, which interacted with different forms of nucleic acids and stabilizes G-quadruplex structures. BMVC suppressed the tumour-related properties of cancer cells, including cell migration, colony-forming ability and anchorage-independent growth. In clinical tests (overall, 114 outpatients), the use of fluorescent BMVC was investigated for the cancer diagnosis (needle aspirates of neck masses). Many analogue derivatives of BMVC have been analysed and used as probes due to the fluorescent electron donating optical chromophore properties of this carbazole derivative. Recently a new derivative has been used for the detection of bcl-2 2345 quadruplex structures.

2.6. Benzopsoralen and 3-hydroxy-N-alkylcarbazole

Benzopsoralen derivatives and its carbazole analogues were synthesized, tested against MDA MB231 (breast carcinoma) and TCC-SUP (urinary bladder cell carcinoma) cell lines, and their mechanism of action was investigated by means of molecular docking studies. Every benzopsoralen and carbazole derivative showed interesting anti-proliferative activities, with GI50 values in the nanomolar range against both cell lines. Among carbazole derivatives, compound 6 (Figure 10) had very strong activity with GI50 values of 0.198 and 0.025 μM against MDA MB231 and TCC-SUP cell lines, respectively.

2.7. MHY407

The carbazole derivative MHY407 (Figure 11) is active against breast cancer cell lines by inhibiting cellular proliferation with IC50 around 5 μM. This compound increased DNA damage and triggered cell cycle arrest in S phase. In combination with various chemotherapeutic treatments, such as doxorubicin, etoposide or radiation, MHY407 improved the efficiency of the treatments by reducing cell viability and increasing apoptosis.

2.8. Amide-containing carbazole derivatives

Amide-containing carbazole derivatives 7a–d and 8 (Figure 12) have been synthesized and their in vitro anti-proliferative activities against NPC-TW01 (nasopharyngeal carcinoma), NCI-H661 (lung carcinoma) and Jurkat (leukaemia) cell lines were evaluated. All carbazole derivatives were inactive or weakly active, with IC50 values ranging from 11.09 to 42.77 μM.
| Patent number       | Year of publication | Inventors          | Title                                                                                                           | Structure |
|---------------------|---------------------|--------------------|-----------------------------------------------------------------------------------------------------------------|-----------|
| EP2403855 B1        | 2013                | Ahmed et al.       | Hybrids of carbazole-bound pyrrolo[2,1-c][1,4]benzodiazepine as potential anti-cancer agents and their method of preparation¹⁹ |           |
| US8815840 B2        | 2014                | Purandare et al.   | Carbazole and carboline kinase inhibitors²⁰                                                                   |           |
| WO2012059232 A1     | 2012                | Demotz S et al.    | Carbazole and carboline derivatives, their preparation and therapeutic applications thereof²¹                    |           |
| US20120184590 A1    | 2012                | Rawjewski et al.   | Formulations of indole-3-carbinol derived antitumour agents with increased oral bioavailability²²             |           |
| WO2013121385 A1     | 2013                | Rault et al.       | Use of carbazole-phenone derivatives for treating cancer²³                                                    |           |
| WO2014134232 A1     | 2014                | Poss et al.        | Carbazole compounds useful as bromodomain inhibitors²⁴                                                        |           |
| US20160024083 A1    | 2016                | Gurova et al.      | Compounds and methods for treating cancers²⁵                                                                   |           |
| US20140303224 A1    | 2014                | Tucker et al.      | Carbazole compounds and therapeutic uses of the compounds²⁶                                                    |           |

(continued)
2.9. Murrayafoline-A

Isolated from *Murraya euchrestifolia* (Rutaceae), 13 carbazole alkaloids were evaluated against HL-60 leukaemia cell line. Murrayafoline A (Figure 13) displayed a significant interaction with the caspase-9/caspase-3 pathway, leading to the cellular apoptosis.

2.10. Clauszoline-I

Extracted from *Clausena vestita* Tao, clauszoline-I (Figure 14) showed effective ability to induce the cell cycle arrest in the S and G2/M phases. The mechanism is linked with the inhibition of the phosphorylation of the Ser-643 of the protein kinase C delta (PKCδ). PKCδ is a prototypical class of serine/threonine kinases, and implicated in nearly all stages of cancer, and the induction of the cell cycle arrest. Clauszoline-I displayed a growth inhibitory activity against four cancer cell lines (cervical carcinoma, glioblastoma, nasopharyngeal carcinoma, hormone-independent breast cancer), with IC50 values in the micromolar range (13.3–71.6 µM).

2.11. 6-Methoxy-1,4-dimethyl-N-alkylcarbazole derivatives

Synthesized N-alkylcarbazole derivatives 9a–c (Figure 15) showed interesting anti-proliferative activities. Their selective properties allowed the suppression of STAT3 phosphorylation, which led to the decrease of its mediated transcription with inhibition of 50, 90 and 95%, respectively.

2.12. Excavatine A

A carbazole alkaloid, excavatine A (Figure 16), was isolated from the stems and leaves of *Clausena excavata* BURM. f. (Rutaceae) and its cytotoxic activities against A549 lung carcinoma and HeLa cervix adenocarcinoma cell lines were assessed, showing IC50 values of 17.77 and 6.47 µM, respectively.

2.13. Clausenawalline F

Twenty-two compounds were isolated from the roots of *Clausena wallichii* (Rutaceae) and tested for both anti-bacterial and cytotoxic activities. After evaluations, clausenawalline F (Figure 17) exhibited the highest cytotoxicity with IC50 values of 10.2 µM against KB, a subline of the ubiquitous keratin-forming tumour cell line, and of 4.5 µM against NCI-H187 small-cell lung cancer cell line.

2.14. 2-[(9-Ethyl-9H-carbazol-3-yl)amino]-2-oxoethyl N,N-disubstituted dithiocarbamate derivatives

Carbazole derivatives bearing dithiocarbamate group showed cytotoxic activity on C6 glioma and A549 lung carcinoma cell lines: analysis of DNA synthesis and detection of apoptosis by flow cytometry were set up. Çiftçi et al. reported that compound 12 (Figure 18) was the most active against C6 cell line (IC50 value of 4.5 µM) and A549 cell line (IC50 value of 10.2 µM).

---

**Table 1. Continued.**

| Patent number | Year of publication | Inventors | Title | Structure |
|---------------|---------------------|-----------|-------|-----------|
| US2017158636 A1 | 2017 | James et al. | Functionalized and substituted carbazoles as anti-cancer agents | ![Structure](image1) |
| US2017166526 A1 | 2017 | Narayanan et al. | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | ![Structure](image2) |
of 12.2 μM) but showed less activity against A549 (IC50 value of 84.7 μM). Compounds 10 and 11 (Figure 18) showed interesting activity against C6 cell line, with IC50 values of 62.7 and 49.9 μM, respectively7,46.

2.15. EHop-016

EHop-016 was serendipitously discovered to be the most potent Rac1 inhibitor. The small GTPase Rac1 is a member of the Ras superfamily of GTPases and has been implicated in the regulation of cellular migration and invasion in breast cancer cells. EHop-016 reduced metastatic cancer cell viability at a concentration inferior to 5 μM. Additionally, its anti-cancer activity (tumour growth and metastasis) was demonstrated in vivo by using a mouse model of breast cancer. The carbazole group contributed to Rac1 inhibitory activity and then new compounds 13a and 13b (Figure 19) were designed and synthesized. The most potent Rac1 inhibitor was 13b, which inhibited by 55% at a concentration of 250 nM and was four times more potent inhibitor of Rac1 than EHop-016 with reduced cellular toxicity47.

2.16. Carbazole-3,6-diamine derivatives

Carbazole derivatives bearing diamine groups presented a new potential for telomerase inhibition. Using three different docking programs (CDOCKER, Ligandfit, Autodock) and interaction analysis demonstrated that compounds 14a and 14b (Figure 20) had the best telomerase inhibition activity more interestingly with the introduction of a pyrazole ring48.

2.17. Carbazole sulfonamide derivatives

The carbazole sulfonamide IG-105 (Figure 21) was described as a potent anti-mitotic agent that inhibited microtubule assembly through specific interactions within the tubulin structure. The introduction of a hydroxyl group (7-OH) on the carbazole-ring increased the solubility and provided a new derivative named SL-3–19 (Figure 21). This compound was active against HepG2 liver cancer (IC50 = 12 nM) and MCF-7 (IC50 = 14 nM) breast cancer cell lines. The IC50 of the positive controls podophyllotoxin and combretastatin CA-4 against HepG2 were 3 and 2 nM, respectively, and against MCF-7 (IC50 = 20 and 5 nM, respectively). Niu et al. described further investigations on the anti-oesophageal squamous cell carcinoma (ESCC) activity and mechanisms of SL-3–19 in vitro and in vivo. Mechanistically, SL-3–19 inhibited ESCC cell growth by inducing cell apoptosis and arresting the cell cycle at G2/M phase in a dose-dependent manner. In addition to microtubule assembly inhibition, this compound showed a significant disruption of the vascular structure by obstructing the formation of capillary-like tubes in vitro and the growth of ESCC xenografts and microvessel density in vivo50.

2.18. Trimethoxybenzamide and trimethoxyphenylurea

Two 1,4-dimethylcarbazole derivatives (Figure 22), trimethoxybenzamide 15 and trimethoxyphenylurea 16, were active against both HL60 (acute promyelocytic leukaemia) and KB (a subline of HeLa) cell lines. These compounds are potent cell proliferation inhibitors, especially 15 that showed the best activities with IC50 values of 5.3 μM against HL60 cells and 6.7 μM against KB cells. The anti-proliferative activity was correlated with the inhibition of tubulin polymerization, which ranged from 20 to 50% inhibition51.
2.19. Guanidinocarbazoles

Several alkylguanidines derived from carbazole were prepared and tested for their anti-cancer activity. Three compounds 17a-c (Figure 23) were tested at 10⁻⁵ M against KB and HeLa cell lines, and the best IC₅₀ values (3.1, 3.5 and 4 mM, respectively) against HL60 acute promyelocytic leukaemia cell line. Compound 17a, which was found to be the most active, also demonstrated a high inhibition at 10⁻⁵ M against MCF-7, HCT116, PC3 (prostate cancer) and MRC5 (human fatal lung fibroblast) cell lines. Furthermore, fluorescence measurements were carried out and showed that 17a had some DNA binding properties, which was described as a cycle-dependent cytotoxic activity.

In summary, various pharmacomodulations in the series of tricyclic carbazoles were performed to obtain new anti-tumour compounds and to investigate the structure–activity relationships. Several substituents were essentially introduced on the nitrogen atom of the indole moiety or on the benzene moiety. Figure 24 shows the substituents that have contributed to the improvement of the anti-tumour activity of the compounds described in this section.

3. Tetracyclic fused carbazoles

3.1. Tetracyclic carbazoles containing a 5-membered ring

3.1.1. Cyclopenta[c]carbazoles

A synthesized series of cyclopenta[c]carbazoles were investigated as a p53 activator using two cell lines, HT1080 (lung fibrosarcoma)
and RCC45 (renal cell carcinoma) cell lines. The highest activity (EC₅₀ value of 0.08 μM) was observed with compound 18 (Figure 25) having an acetyl group at C6 and N9 substituted with (1-methylpyrrolidin-2-yl)ethyl.

3.1.2. Furanocarbazoles

Fourteen compounds, including mafaicheenamines D and E, were isolated from the roots of Clausena lansium (Rutaceae) and evaluated against KB, MCF-7 and NCI-H187 cell lines. All compounds were non-cytotoxic against the tested cell lines, except mafaicheenamine E with a methoxy group at C1 and bearing a substituted furanone ring on C₂-C₃ (Figure 26) which exhibited...
cytotoxicity against MCF-7 cell line with an IC\textsubscript{50} value of 10.1 μM\textsuperscript{54}.

3.1.3. Pyrrolocarbazoles
Santio et al.\textsuperscript{55} first described the activity of 1,10-dihydropyrrolo[2,3-\textit{a}]carbazole-3-carbaldehyde (DHPCC-9, compound 19a, Figure 27) as a potent and selective inhibitor for all Pim family members. Novel \textit{N}-10-substituted pyrrolo[2,3-\textit{a}]carbazole-3-carbaldehyde derivatives\textsuperscript{56} were synthesized and evaluated as Pim kinase inhibitors\textsuperscript{57,58}. All cited compounds in Figure 27 showed inhibitory activity of Pim kinases, especially Pim-1 and Pim-3 with IC\textsubscript{50} comprised between 46 and 490 nM. In vitro anti-proliferative activity of compounds 19f, 19g and 19h was also evaluated using primary human fibroblasts and three human solid cancer cell lines (PA1, PC3 and DU145). These three compounds presented anti-proliferative activities in a micromolar range. Among them, 19h was the most active compound (0.486 < IC\textsubscript{50} < 0.96 μM)\textsuperscript{7}.

Derivatives of \textit{N}-10-bridged pyrrolo[2,3-\textit{a}]carbazole-3-carbaldehyde\textsuperscript{7} showed interesting inhibitory properties, especially with compounds 20a and 20b (Figure 28). Both molecules were presented as Pim-1 and Pim-3 inhibitors (IC\textsubscript{50} from 0.009 to 0.05 μM).
In parallel, compounds 20a and 20b with a longer alkyl N1–N10 bridge exhibited apoptosis-inducing activity toward IPC-81 (acute myeloid leukaemia) cells, but not toward normal fibroblasts\(^59\).

Other pyrrolo[2,3-a]carbazole derivatives with substituent on position 4 were synthesized and their biological activities were evaluated as Pim kinase inhibitors and in vitro anti-proliferative agents. Compound 21 (Figure 29), bearing a methoxycarbonyl group at the 4-position, was found to be active, especially on Pim-3 kinase with IC\(_{50}\) around 0.5\(\mu\)M. The latter also showed anti-proliferative activities on fibroblasts (IC\(_{50}\) = 8\(\mu\)M) and on PC3 cells (IC\(_{50}\) around 6\(\mu\)M)\(^60\).

Natural \(\text{C-glycosyl pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione derivatives were tested as Checkpoint kinase 1 (Chk1) inhibitors. Compounds } 22 \text{ and } 23 \text{ (Figure 30) substituted at the C1 with a glycosyl group and at C6 with a hydroxyl group were the most active compounds among this series and exhibited IC}_{50} \text{ values from 0.5 to 9.5}\mu\text{M.}\)

3.1.4. Pyrazolocarbazoles
A series of pyrazolocarbazoles [3,4-c] and [4,3-c] carbazoles was synthesized and tested. Among 3,6-dihydropyrazolo[3,4-c]carbazoles, compound 24 (Figure 31) demonstrated to potently inhibit Pim-1 and Pim-3 kinases (IC\(_{50}\) from 0.04 to 0.1\(\mu\)M) and also to be active against proliferative activities of prostatic cancer cells PC3 (IC\(_{50}\) was around 3\(\mu\)M). A 1,6-dihydropyrazolo[4,3-c]carbazole, compound 25 (Figure 31), showed the best Pim kinase inhibitory potency toward Pim-3 (IC\(_{50}\) around 0.09\(\mu\)M)\(^62\).

3.1.5. Isoxazolocarbazoles
A series of carbazole analogues comprising pyrido, isoxazolo, pyrimido and pyrazolo templates were synthesized and evaluated for their cytotoxicity against AGS (gastric cancer) and HeLa cell lines. Among the tested derivatives, 3-(3',4'-diethoxyphenyl)-9-methyl-4,5-dihydro-10H-isoxazolo[3,4-a]carbazole (compound 26, Figure 32) stood out with an IC\(_{50}\) value of 0.37\(\mu\)M against HeLa cells, which was 11 times fold better than the standard ellipticine. All the compounds exhibited a strong in vitro and selective cytotoxicity against HeLa and moderate activities against AGS cell line\(^63\) (for compound 26, IC\(_{50}\) of 15.12\(\mu\)M).

Briefly, when comparing the mentioned tetracyclic carbazoles containing a five-membered ring, SAR study can be correlated with substitutions at the carbazole ring (Figure 33).

3.2. Tetracyclic carbazoles containing a six-membered ring
3.2.1. Benzocarbazoles
Alectinib/CH5424802 (compound 27a, Figures 2 and 34) is the second generation ALK inhibitor bearing a 5H-benzo[b]carbazol-11(6H)-one structural scaffold which presented a high selective ALK inhibition at a nanomolar scale (IC\(_{50}\) value of 1.9\(\text{nM}\))\(^64\). Additionally, it is a potent anti-proliferative compound against KARPAS-299 cell line (human T cell lymphoma) carrying the nucleophosmin (NPM)-ALK fusion gene with an IC\(_{50}\) value of 3.0\(\text{nM}\). In vivo studies in mice, using ALK fusion gene-positive NSCLC xenograft model, showed that orally administrated compound 27a significantly regressed tumours. Currently, this compound is being evaluated in phase I/II clinical trials for the treatment of ALK-positive NSCLC\(^65\).

Compared to the first generation non-carbazole derivative crizotinib (Figure 35), in vitro and in vivo studies showed that alectinib was more potent and selective against wild and mutant ALK. Kodama et al.\(^66\) showed that the inoculation of alectinib reduced the tumour size and avoided its regrowth. As previously mentioned, alectinib received in 2015 approvals by FDA and EMA for anti-cancer use.
A series of 2-(4-aminobenzosulfonyl)-5H-benzo[b]carbazole-6,11-dione derivatives has been synthesized. In vitro anti-proliferative activity was performed against SiHa (cervical carcinoma) cell lines. Compounds 28, 29a,b (Figure 36) exhibited a good cytotoxicity with IC50 values of 52.2, 53.8 and 33.5 μM, respectively. The interaction between all compounds and HDAC8 was also carried out by performing molecular docking studies with the use of the GLIDE program.

3.2.2. Pyranocarbazoles

Girinimbine (Figure 37), a carbazole alkaloid isolated from the stem bark of M. koenigii, had a strong anti-tumour promoting activity. The expression of the Epstein–Barr Virus Early Antigen (EA-EBV) in Raji cells was inhibited by more than 90% when tested at 16 μg/mL (50% inhibition at 22.8 μM). The compound did not alter Raji cell's viability due to very low cytotoxicity. Girinimbine showed strong anti-oxidant properties comparable to α-tocopherol.
(vitamin E) and inhibited the superoxide generation in the 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced differentiated HL-60 cells.

A series of pyrano[3,2-c]carbazole derivatives (Figure 38) showed interesting anti-proliferative activity on different cancer cell lines such as MDA-MB-231, K562, A549 and HeLa with IC_{50} values ranging from 0.43 to 8.05 μM. The MTT cell proliferation and tubulin polymerization assays demonstrated that these compounds induced a G2/M arrest of the cell cycle by inhibiting tubulin and disrupting the microtubule network. The caspase-3 assay demonstrated that the cell death occurred by apoptosis.

Mahanine (3,5-dimethyl-3-(4-methylpent-3-en-1-yl)-3,11-dihydropyrano[3,2-a]carbazol-9-ol, Figure 39) has been tested in several studies as a single compound or in combination for anti-cancer therapy, for example HCT116 (IC_{50}=25.5 μM), HeLa (IC_{50}=24.3 μM) and AGS (IC_{50}=33.8 μM) cancer cell lines were employed. It showed a growth inhibitory effect with IC_{50} in the micromolar range (from 12.6 to 33.8 μM). Mahanine is also a DNA intercalative cytotoxic molecule, which presented anti-oxidant capacities. On human cancer cell lines, it indicated excellent radical scavenging of the 2,2-diphenyl-1-picrylhydrazyl radical (DPPH•, 9.2 μM), 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid radical (ABTS•+, 6837.5 μmol Trolox/g), OH• (12.0 μM) and nitric oxide radical (NO•, 7.8 μM). Mahanine showed as well alpha-glucosidase inhibitory activity with IC_{50} value of 21.4 μM.

Das et al. reported that the combination of mahanine with 5-fluourouracil enhanced the reactive oxygen species (ROS) production, increased the activation of tumour suppressor proteins and suppressed chemo-migration. In another study, the same authors reported that when associated to cisplatin, mahanine
could overcome cisplatin-toxicity and drug resistance. Mahanine synergically improved the apoptosis induced by cisplatin in cervical cancer cells and inhibited migration property. The combination at molar ratio 1:4 of cisplatin: mahanine showed a growth inhibitory effect on HeLa and SiHA cell lines (IC50 of 1.6–1.8 µM, respectively). This effect on cell inhibition was 10 times higher to the inhibition induced only by mahanine.

### 3.2.3. Pyridocarbazoles

The commercial analogue of ellipticine, Celiptium (Figure 1), is active against metastatic breast cancer and acts as an inhibitor of type II topoisomerase. Several studies have also reported apoptosis induction by ellipticine involving the p53 tumour suppressor protein. Prudent et al.73 have recently reported a novel mechanism of action of ellipticine as a new inhibitor of the casein kinase CK2 and new analogues are currently developed.

Mori et al.74 reported the synthesis of new ellipticine and pyridocarbazole derivatives and their evaluation against HeLa S-3 cell lines. Most of the compounds showed anti-tumour activity with IC50 values between 2.50 µM and 60 µM. It appeared that compound 31 (Figure 40), an ellipticinium-analogue linked to a methyl nitrosourea group, showed the best anti-tumour activity with an IC50 value of 1.3 µM which was two times more potent than ellipticine (2.1 µM).

Quantitative structure activity analysis (QSAA) was carried out on olivacine and compounds 32a–i (Figure 41) using the software TSAR to determine the structural features responsible for their activity75.

Hetero annulated carbazoles were designed, synthesized and their in vitro cytotoxicity was evaluated against HeLa and MCF-7 cell lines by MTT assay and compared to the standard drug ellipticine. Compound 33 (Figure 42) demonstrated 1.2-fold stronger activity than ellipticine’s cytotoxic activity against HeLa. Then, molecular docking studies were carried out using CK2 as a target, in which compound 33 showed the lowest binding energy and best ligand efficiency76. SAR studies revealed that, the compound bearing the pyrimido moiety and the electron-withdrawing chlorine in the carbazole displayed excellent cytotoxic activity (IC50 value of 8.11 µM) against HeLa cells.

The in vitro cytotoxicity of the pyrido[2,3-α]carbazoles was evaluated by SRB (sulfo-rhodamine B) assay against MCF-7, HeLa and AS49 cell lines. Among these derivatives, compound 34 (Figure 43) showed the best activity with an IC50 of 13.42 µM against HeLa cells. All the designed compounds demonstrated a higher potency against HeLa than against the other tested cell lines77.

Pyrido[3,2-α]carbazole derivatives and their analogues were tested against A549 and HT29 cell lines with IC50 values ranging from 0.07 µM to 4.45 µM. For example, compound 35 (Figure 44) was active against A549 cells with an IC50 value of 0.07 µM and with 0.11 µM against HT29 Cells78.

Ditercalinium is a dimer of two 7H-pyrido[4,3-c]carbazole units (Figure 45). It is a bis-interacting agent in the major groove of DNA. NMR studies and X-ray crystal structure revealed that both rings of the dimer allowed intercalation with base pairs and caused structural changes in the DNA79.

### 3.2.4. Pyrimidocarbazoles

Among pyrimidocarbazole derivatives 36a–d (Figure 46), 2-amino-4-(3’-bromo-4’-methoxyphenyl)-8-chloro-11H-pyrimido[4,5-α]carbazole 36d showed the best cytotoxic efficacy against both MCF-7

![Figure 35. Chemical structures of crizotinib (Xalkori®), a second generation of ALK inhibitors.](image)

![Figure 36. Chemical structures of 2-(4-amino-benzosulfonyl)-5H-benzo[b]carbazole-6,11-diones 28 and 29a,b.](image)

![Figure 37. Chemical structure of girinimbine.](image)
and A-459 cancer cell lines (IC$_{50}$ value of 20 and 25 μM, respectively). Compounds 36a–c also exhibited stronger cytotoxic activity against MCF-7 cell lines.$^8$0.

3.2.5. Oxazinocarbazoles

A set of various oxazinocarbazoles was synthesized$^8$1 and their activities were studied using a CE-based assay for CK2 activity measurement, a cytotoxicity assay using IPC-81 cells. Three oxazinocarbazoles 37a–c (Figure 47) showed CK2 inhibition with IC$_{50}$ values of 8.7, 14.0 and 1.40 μM, respectively. Another test using again the IPC-81 cells was then performed, and those compounds demonstrated the ability to induce leukaemia cell death with IC$_{50}$ values between 57 and 62 μM.$^8$1.

3.2.6. Miscellaneous

A pyridine ring at C$_2$-C$_3$ and the substitution of C$_1$ with an EWG, improved the activity. The insertion of a methyl group on C$_4$ increased the lipophilicity.

The substitution with methylisothiourea group showed the best antitumor activity.

The phenyl ring substitution with moderate EDG showed the best activity on breast cancer cell lines.

and A-459 cancer cell lines (IC$_{50}$ value of 20 and 25 μM, respectively). Compounds 36a–c also exhibited stronger cytotoxic activity against MCF-7 cell lines.$^8$0.

3.2.5. Oxazinocarbazoles

A set of various oxazinocarbazoles was synthesized$^8$1 and their activities were studied using a CE-based assay for CK2 activity measurement, a cytotoxicity assay using IPC-81 cells. Three oxazinocarbazoles 37a–c (Figure 47) showed CK2 inhibition with IC$_{50}$ values of 8.7, 14.0 and 1.40 μM, respectively. Another test using again the IPC-81 cells was then performed, and those compounds demonstrated the ability to induce leukaemia cell death with IC$_{50}$ values between 57 and 62 μM.$^8$1.

3.2.6. Miscellaneous

The cytotoxicity of three dihydro-4H-pyrido[3,2,1-j]carbazole derivatives was evaluated against HeLa cell lines. Carbazoles 38, 39 and 40 (Figure 48) showed moderate activity with IC$_{50}$ values of 19.80, 17.46 and 18.76 μM, respectively.$^8$2.
**Figure 41.** Chemical structures of olivacine and derivatives 32a–i used for 2D QSAR analysis.

**Figure 42.** Chemical structure of hetero annulated carbazole compound 33.

**Figure 43.** Chemical structure of the pyridocarbazole 34.
Figure 44. Chemical structure of pyridocarbazole 35.

Figure 45. Chemical structure of ditercalinium.

Figure 46. Chemical structures of pyrimido[4,5-a]carbazole derivatives 36a–d.
3.3. Tetracyclic carbazoles containing a 7-membered ring

3.3.1. 1,4-Thiazepan-3-ones fused carbazoles

Several 1,4-thiazepine derivatives fused with carbazole skeleton underwent in vitro cytotoxic studies. Compounds 41a–f (Figure 50) showed selective cytotoxicity towards HCT 116 cell lines with inhibition rates of 51.57–62% at 1 mg/mL.

4. Pentacyclic fused carbazoles

4.1. Pentacyclic fused carbazoles containing two 5-membered rings

A series of 3-substituted-pyrrolocarbazole analogues (3-aryl-derived pyrrolocarbazoles) was synthesized and evaluated as...
PARP-1 inhibitors. They were also tested in a cell-based assay that evaluated their ability to attenuate the depletion of NAD\(^+\) levels following hydrogen peroxide insult in PC12 (rat pheochromocytoma) cells. Results showed that two analogues, compounds 42a and 42b (Figure 51), displayed potent enzyme activity with IC\(_{50}\) values of 18 and 25 nM, respectively, as well as high cell permeability (100% NAD\(^+\) recovery at 30 \(\mu\)M)

4.2. Pentacyclic fused carbazoles containing a five-membered ring and a six-membered ring

4.2.1. Tetrahydroindolo[2,3-b]carbazoles
Tetrahydroindolo[2,3-b]carbazoles were synthesized to undergo a one dose screening at 10\(^{-5}\)M, followed by a five dose screening for the best compounds using the NCI 60 cell lines list. Compound
(Figure 52) exhibited the highest anti-cancer activity with growth inhibition at lowest mean value of 21.63%, and GI50 values ranging from 1.07 to 9.56 μM against the tested cell lines. Several inert metal complexes such as pyridocarbazole-rhodium (III) were synthesized and characterized by X-ray crystallography. Stability studies were carried out including evaluation of Pim-1 kinase inhibitory activity. Compound (Figure 53) was found to be a stable rhodium (III) complex and extremely potent inhibitor of Pim-1 kinase (IC50 around 160 pM).

The iridium–pyridocarbazole complexes 45a and 45b (Figure 54) are highly photocytotoxic compounds. Their anti-angiogenic properties were investigated in a 3D angiogenesis assay. It resulted that 45a and 45b are light-independent potent anti-angiogenic agents, very active on the vascular endothelial growth factor.

4.3. Pentacyclic carbazoles containing two six-membered rings

4.3.1. 7H-Dibenzo[c,g]carbazole

7H-Dibenzo[c,g]carbazole (DBC), benzo[a]pyrene (B[a]P) (Figure 55) and several binary mixtures of both compounds were assessed. The biological activity of the binary mixtures was investigated in the HepG2 and WB-F344 (liver cancer) cell lines and the Chinese hamster V79 cell line. These compounds showed an important biological activity on human carcinogens acting on a micro cellular level by modifying cytochrome CYP1A1 expression.

4.3.2. Murrayazolinine

Murrayazolinine (Figure 56) was isolated from M. euchrestifolia (Rutaceae) and was evaluated against HL-60 cell line. Murrayazolinine displayed a significant interaction with the caspase-9/caspase-3 pathway, leading to the cellular apoptosis.

4.3.3. Carbazole–amonafide structural hybrids

Preliminary anti-proliferative assays revealed that structural hybrids [4,5-bc]carbazole-amonafide derivatives possessed a good cytotoxic activity with IC50 values in the sub-micromolar to micromolar range against HTC116 cell line, and were also selective for cancer.
cells when compared to a HEK293 (non-cancerous human embryonic kidney) cell line. Compound 46 (Figure 57) was the lead candidate with an IC50 value of 0.8 μM against HTC116 cell line and an IC50 value above 40 μM against normal cells89.

5. Hexacyclic fused carbazoles

5.1. Indenopyrrolocarbazoles

A strong lead candidate, compound 47 (Figure 58), was synthesized from staurosporine aglycone (K252c)90. The structure–activity relationship showed that compound 47 is a powerful tropomyosine kinase TrkA inhibitor; therefore, it was selected as a proof of concept for in vitro and in vivo studies53.

5.2. Indazolopyrrolocarbazoles

11–(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981) (Figure 59) is a potent orally active inhibitor of multiple tyrosine kinase receptors (e.g. tyrosine kinase with immunoglobulin and EGF homology domains (TIE2), vascular endothelial growth factor receptor (VEGFR 1–3) and fibroblast growth factor receptor,
FGFR1), which are potent targets for tumour angiogenesis and vascular maintenance. Furthermore, CEP-11981 exhibits excellent permeability, metabolic stability and pharmacokinetic properties. It was advanced into full development and was in clinical phase I study.

5.3. Indolopyrrolocarbazoles

Among the carbazole derivatives, four synthetic indolopyrrolocarbazoles (Figure 60) are currently in clinical trials for cancer therapy. CEP-2563 is active against MTC (medullary thyroid carcinoma) and blocked tyrosine kinase receptors such as Trk family and the platelet-derived growth factor (PDGF) receptor tyrosine kinase. Edotecarin (J-107088) and becatecarin (XL119) which both could intercalate into DNA and edoteacrin could additionally stabilize the DNA–topoisomerase I complex. Edotecarin (J-107088) was advanced into full development and was in clinical phase I study.

5.3.1. Staurosporine and analogues

A series of indolocarbazoles and staurosporine analogues (Figure 61) were synthesized and tested as anti-proliferative agents against HUVEC (Human Umbilical Vein Endothelial Cells), LoVo (colorectal adenocarcinoma), DLD-1 (colorectal adenocarcinoma) and ST-486 (Burkitt’s lymphoma) cell lines. Their anti-angiogenesis activity was also investigated by capillary tube formation in 3-D matrigel matrix. Acero et al. observed on all cell lines that the dimethylaminoalkyl chain in R1 (Figure 61) enhances both activity and selectivity. Analog 48 (Figure 61), with an IC50 of 0.1 μM against HUVEC, was one of the most active compounds and the most selective one. The in vivo anti-angiogenic assay using the Lewis lung mice carcinoma model revealed that no tumour reduction was observed, although a slight reduction in metastasis number was noticed.

5.3.2. Streptocarbazoles A and B

Isolated from the marine-derived actinomycetes strain Streptomyces sp. FMA, streptocarbazoles A and B (Figure 62) were tested as anti-tumoural agents. Streptocarbazole A was cytotoxic against HL-60, A-549 (lung carcinoma), P388 (leukaemia) and HeLa cell lines, with IC50 values of 1.4, 5.0, 18.9 and 34.5 μM, respectively, and could arrest the cell cycle of HeLa cells at the G2/M phase (at a concentration of 10 μM). Streptocarbazole B was only
5.3.3. Methylenedioxy- and ethylenedioxy-fused indolopyrrolocarbazoles

The biological activity of indolo[2,3-α]carbazole derivatives (Figure 63) was determined as potential anti-cancer agents. Among the analogues, compounds 49a–d were the most potent compounds against human topoisomerase I and exhibited inhibitory activities with IC₅₀ values in the micromolar range (from 3.2 to 5.4 μM)⁹⁶.

In summary, the scaffold pyrrolocarbazole was extensively used as a part of hexacyclic fused carbazoles. Three sub-series of related compounds were developed, namely indeno-, indazo- and indolo-pyrrolocarbazoles (Figure 64). For some the additional presence of a sugar moiety is also to notice (e.g. edotecarin, compounds 49a–d). It is an important point to modulate their physicochemical properties such as hydrosolubility and then to facilitate in vivo investigation.

5.4. Indolopyrazolocarbazoles

Glycosylated indolopyrazolocarbazole analogues of K252c (Figure 58) have been synthesized to improve their cellular potencies leading to two compounds: 13-(1-deoxy-β-D-glucopyranos-1-yl)-12,13-dihydro-5H-indolo[2,3-α]pyrazolo[3,4-c]carbazole 50 and 12-(1-deoxy-β-D-glucopyranos-1-yl)-12,13-dihydro-5H-indolo[2,3-α]pyrazolo[3,4-c]carbazole 51 (Figure 65)⁹⁷. Interestingly, compounds 50 and 51 were active toward HCT116 (human colon carcinoma) cell line with similar IC₅₀ values of 12 and 11 μM, respectively.

5.5. Indolopyrimidocarbazoles and related

A series of indolo[2,3-α]pyrimido[5,4-c]carbazoles and azaindolopyrimidocarbazoles was synthesized and their anti-cancer activity...
was evaluated through topoisomerase II inhibition and in cellulo assay using the NCI-60 cell line. Although no topoisomerase II inhibition was observed, compound 52a (Figure 66) was found to inhibit in vitro the growth of HCT-15 (colon carcinoma), SK-MEL-2 (melanoma), and ACHN, CAKI-1 and UO-31 (renal adenocarcinoma) cell lines with GI50 values in the low micromolar range. The less toxic azaindolocarbazole 52b (Figure 66) also showed cytostatic activity against NCI-H522 (non-small-cell lung cancer) and UO-31 cell lines.

In the particular point of the replacement of the pyrrolo moiety of indolopyrrolocarbazole either by a pyrazolo or by a pyrimido ring systems (Figure 67), new active hexacyclic derivatives demonstrated cytotoxic activity on colon carcinoma cell lines (e.g. HCT116, HCT-15).

6. Heptacyclic fused carbazoles

6.1. Carbazole derivatives of ursolic acid

A series of carbazole derivatives of ursolic acid was synthesized and assayed against two human liver cancer cell lines (SMMC-7721 and HepG2) using the MTT colorimetric method. From the results, compounds 53a-f (Figure 68) displayed pronounced cytotoxic activities with IC50 values below 10 μM. Compound 53e was found to be the most active compound with IC50 values of 1.08 ± 0.22 and 1.26 ± 0.17 μM against SMMC-7721 and HepG2 cells, respectively, comparable to those of doxorubicin. In addition, 53e showed reduced cytotoxicity against noncancerous LO2 cells with an IC50 value of 5.75 ± 0.48 μM.

7. Conclusion

Cancer is a very complex disease and the increase of the biological targets can be synergistically coordinated to relieve patients from cancer burden. Many new cancer therapies have been developed in the last years, but this research field still presents many challenges. Among the natural products, the carbazole alkaloids have shown several biological activities (Figure 69). Since 2012, we presented the major anti-tumoural activities of natural and synthetic carbazole derivatives.

In a recent study, Iman et al. showed that the combination of many mechanisms of action were observed in the case of giri-nimbine which resulted in an induction of G0/G1 phase arrest, an upregulation of two cyclin-dependent kinase proteins p21 and p27, an activation of caspase-3 and caspase-9, downregulation of Bcl-2 and upregulation of Bax in giri-nimbine-treated cells. Another activity was seen on the upregulation of p53. Induction of apoptosis by giri-nimbine was also investigated in vivo by using zebrafish embryos, with results demonstrating significant distribution of apoptotic cells in embryos after a 24-h treatment period. Some compounds are currently following clinical trial phases and the optimal structure has not yet been found. Carbazole derivatives have been recently described by Diaz et al. for their anti-tumour activity with the microtubule targeting and could inhibit tubulin assembly. Many potential compounds can be the future candidate for the cancer chemotherapy, with the purpose of a multi-target therapy.

Acknowledgements

Dr Samar Issa also thanks Dr Florence Dufour for her scientific support.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This work was supported by the “Partenariats Hubert Curien” (PHC) (Campus France, Program Aurora, Grant Agreement No. 27460VC), by the Norwegian Research Council (Grant Agreement No. 213191/F11) and the Norwegian Cancer Society (Project no.: 4529447). Pr. Marc Le Borgne also thanks the “Institut Français d’Oslo” for their support via the Åsgard Program 2010. This scientific work was also supported by financial support from Rhône-Alpes region through an Explô'ra Sup scholarship on 2013.

References

1. WHO methods and data sources for global burden of disease estimates 2000–2015, Department of information, evidence and research WHO, Geneva, January 2017, available at http://www.who.int/healthinfo/global_burden_disease/GlobalDALYmethods_2000_2015.pdf [last accessed 26 Jul 2018].
2. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–86.
3. Schmidt AW, Reddy KR, Knöller H-J. Occurrence, biogenesis, and synthesis of biologically active carbazole alkaloids. Chem Rev 2012;112:3193–328.
4. Knöller H-J, Reddy KR. Isolation and synthesis of biologically active carbazole alkaloids. Chem Rev 2002;102:4303–427.
5. Graebe C, Glazer C. First isolation of carbazole alkaloids: a review. Molecules 2015;20:13496–517.
6. Chakraborty DP, Roy S, Carbazole alkaloids IV. In: The Chemistry of Organic Natural Products. Wien GmbH: Springer-Verlag; 2003; vol. 85:125–230.
7. Bashir M, Bano A, Ijaz AS, Chaudhary BA. Recent developments and biological activities of N-substituted carbazole derivatives: a review. Molecules 2015;20:13496–517.
8. Bajaj YPS. Ochiosa sp.: In vitro production of ellipticine and related compounds. Chem Nat Compd 1990;26:427–428.
9. Sinicropi MS, Iacopetta D, Rosano C, et al. N-thioalkyl-carbazoles derivatives as new anti-proliferative agents: synthesis, characterization, and molecular mechanism evaluation. J Enzyme Inhib Med Chem 2018;33:434–44.
10. Jiang H, Zhang WJ, Li PH, et al. Synthesis and biological evaluation of novel carbazole-rhodanine conjugates as topoisomerase II inhibitors. Bioorg Med Chem Lett 2018;28:
1320–3. (c) Saturnino C, Caruso A, Iacopetta D, et al. Inhibition of human topoisomerase II by new N,N,N-trime-thylthelammonium iodide alkylcarbazole derivatives. ChemMedChem 2018;13:2635–43.
10. Ellipticine acetate, NCI Drug Dictionary, available at https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ellipticine-acetate [last accessed 26 Apr 2018].
11. Alecensia, alecinit, product information, EMA, Human medicines, available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004164/human_med_002068.jsp&mid=WCO0b1ac058001d124 [last accessed 26 Jul 2018].
12. Ruiz-Ceja KA, Chirino YI. Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection. Biomed Pharmacother 2017;90:24–37.
13. Midostaurin approved for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML). US FDA, Approved Drugs, available at https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555756.htm [last accessed 26 Apr 2018].
14. Rydapt, midostaurin, product information, EMA, Human medicines, available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004095/human_med_002155.jsp&mid=WCO0b1ac058001d124 [last accessed 26 Jul 2018].
15. Gutierrez L, Jang M, Zhang T, et al. Midostaurin reduces regulatory T cells markers in acute myeloid leukemia. Sci Rep 2018;8:17544.
16. Stone RM, Manley PW, Larson RA, Capdeville R. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Adv 2018;2:444–53.
17. (a) Janosik T, Rannug A, Rannug U, et al. Chemistry and properties of indolocarbazoles. Chem Rev 2018;118:9058–128. (b) Tsutsumi LS, Gündisch D, Sun D. Carbazole scaffold in medicinal chemistry and natural products: a review from 2010-2015. Curr Top Med Chem 2016;16:1290–313. (c) Shaikh MS, Karpoormath R, Thapliyal N, et al. Current perspective of natural alkaloid carbazole and its derivatives as antitumor agents. Anticancer Agents Med Chem 2015;15:1049–65.
18. (a) Janosik T, Rannug A, Rannug U, et al. Chemistry and properties of indolocarbazoles. Chem Rev 2018;118:9058–128. (b) Tsutsumi LS, Gündisch D, Sun D. Carbazole scaffold in medicinal chemistry and natural products: a review from 2010-2015. Curr Top Med Chem 2016;16:1290–313. (c) Shaikh MS, Karpoormath R, Thapliyal N, et al. Current perspective of natural alkaloid carbazole and its derivatives as antitumor agents. Anticancer Agents Med Chem 2015;15:1049–65.
19. Council of Scientific & Industrial Research (IN). Carbazole-bonded pyrrolo[2,1-c][1,4]benzodiazepine hybrids as potential anticancer agents and process for their preparation. US 8,927,538. 2015.
20. Bristol-Meyers Squibb Co. Carbazole and carboline kinase inhibitors. US 0,058,988. 2012.
21. Philip Morris Products SA. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof. US 0,274,258. 2013.
22. University of Kansas. Formulations of indole-3-carbinol derived antitumor agents with increased oral bioavailability. US 0,184,590. 2012.
23. CNRS. Use of carbazole phenone derivatives for the treatment of cancer. FR 0,051,491. 2012.
24. Bristol-Meyers Squibb Co. Carbazole compounds useful as bromodomain inhibitors. EP 2,961,748. 2018.
45. Maneerat W, Ritthiwigrom T, Cheenpracha S, et al. Bioactive carbazole alkaloids from *Clausena wallichii* roots. J Nat Prod 2012;75:741–6.
46. Çiftçi GA, Temel HE, Yıldırım ŞU, et al. Apoptotic effects of some carbazole derivatives on lung carcinoma and glioma cell lines. Med Chem Res 2013;22:3751–9.
47. Vlaar CP, Castillo-Pichardo L, Medina JI, et al. Design, synthesis and biological evaluation of novel carbazole derivatives as anti-cancer and anti-migratory agents. Bioorg Med Chem 2018;26:884–90.
48. Kalathiya U, Padariya M, Baginski M. Molecular modeling and evaluation of novel dibenzopyrrole derivatives as telomerase inhibitors and potential drug for cancer therapy. IEEE/ACM Trans Comput Biol Bioinforma TCBB 2014;11:1196–207.
49. Sun L, Wu Y, Liu Y, et al. Novel carbazole sulfonamide derivatives of antitumor agent: synthesis, antiproliferative activity and aqueous solubility. Bioorg Med Chem Lett 2017;27:261–5.
50. Niu F, Liu Y, Jing Z, et al. Novel carbazole sulfonamide microtubule-desensitizing agents exert potent antitumor activity against esophageal squamous cell carcinoma. Cancer Lett 2018;420:60–71.
51. Panno A, Sinicropi MS, Caruso A, et al. New trimethoxybenzamides and trimethoxyphenyleureas derived from dimesylcarbazole as cytotoxic agents. Part I. J Heterocycl Chem 2014;51:294–302.
52. Caruso A, Sinicropi MS, Lancelot J-C, et al. Synthesis and evaluation of cytotoxic activities of new guanidines derived from carbazoles. Bioorg Med Chem Lett 2014;24:467–72.
53. Rongved P, Kirsch G, Bouaziz Z, et al. Indenoindoles and cyclopentacarbazoles as bioactive compounds: synthesis and biological applications. Eur J Med Chem 2013;69:465–79.
54. Maneerat W, Ritthiwigrom T, Cheenpracha S, Laphookhieo S. Carbazole alkaloids and coumarins from *Clausena lan- sium* roots. Phytochem Lett 2012;5:26–8.
55. Santio NM, Vahakoski RL, Rainio E-M, et al. Pim-selective inhibitor DHPC9-9 reveals Pim kinases as potent stimulators of cancer cell migration and invasion. Mol Cancer 2010;9:279.
56. Akué-Gédu R, Letribot B, Saugues E, et al. Kinase inhibitory potencies and in vitro antiproliferative activities of N-10 substituted pyrrolo[2,3-a]carbazole derivatives. Bioorg Med Chem Lett 2012;22:3807–9.
57. Letribot B, Akué-Gédu R, Santio NM, et al. Use of copper(I) catalyzed azide alkyne cycloaddition (CuAAC) for the preparation of conjugated pyrrolo[2,3-a]carbazole Pim kinase inhibitors. Eur J Med Chem 2012;50:304–10.
58. Moreau P, Dezhkenova LG, Anizom F, et al. New potent and selective inhibitor of Pim-1/3 protein kinases sensitizes human colon carcinoma cells to doxorubicin. Anticancer Agents Med Chem 2014;14:1228–36.
59. Giraud F, Bourhis M, Nauton L, et al. New N-1,N-10-bridged pyrrolo[2,3-a]carbazole-3-carbaldehydes: synthesis and biological activities. Bioorg Chem 2014;57:108–15.
60. Giraud F, Akué-Gédu R, Nauton L, et al. Synthesis and biological activities of 4-substituted pyrrolo [2,3-a]carbazole Pim kinase inhibitors. Eur J Med Chem 2012;56:225–36.
61. Ichikawa S, Tatebayashi N, Matsuda A. Synthesis of C-glyco-syl pyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as a scaffold for check point kinase 1 inhibitors. J Org Chem 2013;78:12065–75.
62. Suchaud V, Gavara L, Saugues E, et al. Identification of 1,6-dihydropyrazolo[4,3-c]carbazoles and 3,6-dihydropyra-zolo[3,4-c]carbazoles as new Pim kinase inhibitors. Bioorg Med Chem 2013;21:4102–11.
63. Vairaavelu L, Zeller M, Prasad KR. Solvent-free synthesis of heteroannulated carbazoles: a novel class of anti-tumor agents. Bioorg Med Chem 2014;54:12–20.
64. Song Z, Wang M, Zhang A. Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance. Acta Pharm Sin B 2015;5:34–7.
65. Kinoshita K, Asoh K, Furuchi N, et al. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). Bioorg Med Chem 2012;20:1271–80.
66. Kodama T, Tsukaguchi T, Yoshida M, et al. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett 2014;351:215–21.
67. Ravichandiran P, Jegan A, Premnath D, et al. Synthesis, molecular docking and cytotoxicity evaluation of novel 2-(4-amino-benzosulfonyl)-5H-benzol[b]carbazole-6,11-dione derivatives as histone deacetylase (HDAC8) inhibitors. Bioorg Chem 2014;53:24–36.
68. Kok YY, Mooi LY, Ahmad K, et al. Anti-tumor promoting activity and antioxidant properties of girinimbine isolated from the stem bark of *Murraya koenigii* S. Molecules 2012;17:4651–60.
69. Padmaja P, Rao GK, Indrasena A, et al. Synthesis and biological evaluation of novel pyrano[3,2-c]carbazole derivatives as anti-tumor agents inducing apoptosis via tubulin polymerization inhibition. Org Biomol Chem 2015;13:1404–14.
70. Uvarani C, Jaivel N, Sankaran M, et al. Axially chiral bis-carbazoles and biological evaluation of the constituents from *Murraya koenigii*. Fitoterapia 2014;94:10–20.
71. Das R, Bhattacharya K, Sarkar S, et al. Mahanine synergistically enhances cytotoxicity of 5-fluorouracil through ROS-mediated activation of PTEN and p53/p73 in colon carcino-noma. Apoptosis Int J Program Cell Death 2014;19:149–64.
72. Das R, Bhattacharya K, Samanta SK, et al. Improved chemosensitivity in cervical cancer to cisplatin: synergistic activity of mahanine through STAT3 inhibition. Cancer Lett 2014;351:81–90.
73. Prudent R, Moucadel V, Nguyen C-H, et al. Antitumor activity of pyridocarbazole and benzopyridoindole derivatives that inhibit protein kinase CK2. Cancer Res 2010;70:9865–74.
74. Mori R, Kato A, Komori K, et al. Synthesis and in vitro antitumor activity of novel 2-alkyl-5-methoxycarbonyl-11-methyl-6H-pyrido[4,3-b]carbazol-2-ium chloride derivatives. Eur J Med Chem 2014;82:16–35.
75. Sharma M, Agarwal A, Kishore D, Paliwal S. Quantitative structure activity relationship (QSAR) analysis of olivacine polymerization inhibition. Org Biomol Chem 2015;13:1404–14.
76. Indumathi T, Muthusankar A, Shanmughavel P, Prasad KR. Synthesis of hetero annulated carbazoles: exploration of in vitro cytotoxicity and molecular docking studies. MedChemComm 2013;4:450.
77. Indumathi T, Prasad KR. Multicomponent synthesis of pyrido[2,3-a]carbazoles and cytotoxic activity. Med Chem Res 2014;23:4345–55.
81. (a) Issa S, Walchshofer N, Kassab I, et al. Synthesis and anti-
tumor activity of oxazinocarbazole and N,N-bis(carba-
zolylmethyl)amine derivatives. Eur J Med Chem 2010; 45:4:
2567–77. (b) Bouaziz Z, Issa S, Gentili J, et al. Biologically
active carbazole derivatives: focus on oxazinocarbazoles
and related compounds. J Enzyme Inhib Med Chem 2015;
30:180–8.

82. Naik PN, Khan A, Kusurkar RS. Intramolecular Diels–Alder
reaction for the synthesis of tetracyclic carbazoles and iso-
canthines. Tetrahedron 2013:69:10733–8.

83. Shi F, Zeng X-N, Cao X-D, et al. Design and diversity-ori-
ented synthesis of novel 1, 4-thiazepan-3-ones fused with
bioactive heterocyclic skeletons and evaluation of their
antioxidant and cytotoxic activities. Bioorg Med Chem Lett
2012;22:743–6.

84. Dunn D, Husten J, Ator MA, Chatterjee S. Novel poly (ADP-
ribose) polymerase-1 inhibitors. Bioorg Med Chem Lett
2007;17:542–5.

85. El Sayed MT, Ahmed KM, Mahmoud K, Hilgeroth A. Synthesis,
cytostatic evaluation and structure activity relation-
ships of novel bis-indolymethanes and their corre-
spending tetrahydroindolocarbazoles. Eur J Med Chem
2015;90:845–59.

86. Dieckmann S, Riedel R, Harms K, Meggers E. Pyridocarbazole-rhodium (III) complexes as protein kinase
inhibitors. Eur J Inorg Chem 2012;2012:813–21.

87. Kastl A, Wilbuer A, Merkel AL, et al. Dual anticancer activity in a single compound: visible-light-induced apoptosis by an
antiangiogenic iridium complex. Chem Commun Camb
Engl 2012;48:1863–5.

88. Gábelová A, Poláková V, Procházka G, et al. Sustained
induction of cytochrome P4501A1 in human hepatoma cells by co-exposure to benzo[a]pyrene and
7H-dibenzo[c,g]carbazole underlies the synergistic effects
on DNA adduct formation. Toxicol Appl Pharmacol 2013;
271:1–12.

89. Rozovsky A, Regozin E, Oron-Herman M, et al. Synthesis of
antitumor carbazole-amonafide structural hybrids. Eur J Org Chem 2015;2015:1811–8.